Abstract
Abstract Background Xeruborbactam (XERU) is a member of a new class of cyclic boronic acid β-lactamase inhibitors with inhibitory activity against major members of Class A, B, C, and D beta-lactamases. The purpose of these studies was to determine the pharmacodynamic parameter that best described the activity of XERU against Enterobacterales and A. baumannii when administered in combination with a fixed dosage regimen of meropenem in the neutropenic mouse thigh infection model. 24h Free Xeruborbactam AUC vs CRE 24h Free Xeruborbactam AUC vs CRAB Methods Seven carbapenem resistant Enterobacterales (CRE) and six carbapenem-resistant A. baumannii (CRAB) isolates were used in these studies. Mice were rendered neutropenic, infected with ∼107 CFU/thigh and were treated with various doses of XERU in combination with meropenem (300 mg/kg q2h) by the IP route starting 2 hours post infection for 24 hours. The meropenem dosage regimen was fixed and designed to simulate 2 g every 8 hours by 3-hour infusion in humans. Plasma exposures (PK) were measured in neutropenic, infected mice. The relationship between XERU PK-PD indices and the reduction in the log number of CFU per thigh were analyzed by using the sigmoid Emax PD model. Results The activity of XERU was best described by the % 24h free XERU plasma concentrations exceeded 1 mg/L and 24h free xeru plasma AUC. Xeru PK-PD Parameters in Combination with Meropenem against CRE Xeru PK-PD Parameters in Combination with Meropenem against CRAB Conclusion The PK-PD of XERU was best described by the % 24h free XERU plasma concentrations exceeded 1 mg/L and 24h free XERU plasma AUC. The PK-PD of XERU in combination with meropenem and the clinical PK of both drugs support further clinical development for the treatment of carbapenem-resistant isolates of Enterobacterales and A. baumannii. Disclosures Ziad Tarazi, Qpex Biopharma: Employee Niki Roos, n/a, Qpex Biopharma: Employee Ted Page, n/a, Qpex Biopharma: Employee David Griffith, n/a, Qpex Biopharma: Employee.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.